Cancer Gene Therapy Market By Therapy Type (Gene Insertion {Suicide Gene Therapy, Tumor Suppressor Gene Therapy}, Gene Modification {Oncolytic Virotherapy, Antisense and RNAi}, Immunotherapy Based Gene Therapy, Others), By Indication (Breast Cancer, Ovarian Cancer, Liver Cancer, Pancreatic Cancer, Lung Cancer, Prostate Cancer, Others), By End-user (Hospitals, Oncology Institutes, Research Institutes, Biopharmaceutical Companies, Diagnostic Centers, Other), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Therapy Type

• Gene Insertion
  • Suicide Gene Therapy
  • Tumor Suppressor Gene Therapy
• Gene Modification
  • Oncolytic Virotherapy
  • Antisense and RNAi
• Immunotherapy Based Gene Therapy
• Others

By Indication

• Breast Cancer
• Ovarian Cancer
• Liver Cancer
• Pancreatic Cancer
• Lung Cancer
• Prostate Cancer
• Others

By End-user

• Hospitals
• Oncology Institutes
• Research Institutes
• Biopharmaceutical Companies
• Diagnostic Centers
• Other

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Novartis International
• Gilead Sciences, Inc.
• Bluebird Bio, Inc.
• Bristol Myers Squibb Company
• Genmab
• Amgen Inc.
• Spark Therapeutics, Inc.
• Kite Pharma, Inc.
• Zymeworks Inc.
• Sangamo Therapeutics, Inc.
• Autolus Therapeutics
• Adaptimmune Therapeutics
• Celyad Oncology
• Cogent Biosciences
• Merck
• Intellia Therapeutics, Inc.
• CRISPR Therapeutics